Diamonds and Dogs
Turnaround Wednesday. Two days down, two days up. Now what? Most sectors and stocks were higher, but Tesaro (TSRO) had the best day of its trading life with the stock doubling thanks to great news from their phase 3 ovarian cancer trial. Tesaro reported data from its phase 3 NOVA trial, which was testing the ability of its lead compound, niraparib, to treat a few different types of recurrent ovarian cancer. The results were nothing short of fantastic. The study showed that niraparib significantly improved progression-free survival (PFS) in all three of the cohorts that were studied. Patients who were identified as carriers of the germline BRCA mutation demonstrated a PFS of 21 months, far longer than the 5.5 months for the control group. Great news for patients and great news for shareholders.
Thanks to Brexit, Wall Street forgot about the strain of the oil industry. Shares of Eclipse Resources (ECR) plummeted 17% to $3.43 after the company hiked their outlook for production and capital spending, but also announced a huge offering to raise money. The company will fund the capital expenditure plan with a public offering of 37.5 million shares priced at $3.50 per share or more than 10% of their market cap. Plenty of oil and gas companies are still struggling to survive.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.